The effect of nutritional consultation on gastrointestinal complications
Not Applicable
Recruiting
- Conditions
- Condition 1: Abdominal cancer. Condition 2: Pelvic cancer.Malignant neoplasm of other and ill-defined sites (Abdomen)Malignant neoplasm of other and ill-defined sites (Pelvis)
- Registration Number
- IRCT20180610040031N1
- Lead Sponsor
- Sanandaj University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Age 84 -18 years
Diagnostic abdominal and pelvic cavity cancer pathology
Receive abdominal and pelvic cavity radiothrapy
Patients should be at least one-week radiotherapy
Exclusion Criteria
Patients with colon cancer
Chronic digestive disorders
The history of Gluten and Celiac intolerance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ausea. Timepoint: After intervention. Method of measurement: Gastrointestinal Symptom Rating Scale.;Vomiting. Timepoint: After intervention. Method of measurement: Gastrointestinal Symptom Rating Scale.;Abdominal bloating. Timepoint: After intervention. Method of measurement: Gastrointestinal Symptom Rating Scale.;Diarrhea. Timepoint: After intervention. Method of measurement: Gastrointestinal Symptom Rating Scale.;Constipation. Timepoint: After intervention. Method of measurement: Gastrointestinal Symptom Rating Scale.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nutritional consultation's impact on gastrointestinal complications in abdominal and pelvic cancer patients undergoing radiotherapy?
How does nutritional consultation compare to standard-of-care interventions in mitigating radiotherapy-induced gastrointestinal toxicity in abdominal and pelvic malignancies?
Are there specific biomarkers that can predict which abdominal or pelvic cancer patients will benefit most from nutritional consultation during radiotherapy?
What are the potential adverse events associated with implementing nutritional consultation alongside radiotherapy for abdominal and pelvic cancers, and how can they be managed?
What combination approaches or alternative therapies are being explored alongside nutritional consultation to enhance gastrointestinal health in patients receiving radiotherapy for abdominal and pelvic cancers?